TO STAY AHEAD OF PROGRESSION IN RELAPSING MS—
LOOK FOR THESE SIGNS1
Do you have younger adult RMS patients with fewer relapses and accumulating disability?1,2


Or patients living with RMS for 10 years or more and showing increasing disability?1,2
THE FOLLOWING SIGNS MAY SHOW UP IN YOUR RMS PATIENTS SOONER THAN YOU THINK3,4*


Bowel/bladder dysfunction


Trouble with memory or concentration


Weakness or problems with ambulation

Numbness or loss of sensation

Problems with coordination

Difficulty with speech or swallowing


Vision problems


Other neurologic findings related to MS
*As measured by the EDSS.
SUBTLE CHANGES OVER TIME
Not only do symptoms vary from patient to patient, they can often be mistaken for
normal aging or issues unrelated to MS. Consider taking a closer look, as it could be
progression hidden in plain view5,6
SUBTLE CHANGES OVER TIME
Not only do symptoms vary from patient to patient, they can often be mistaken for normal aging or issues unrelated to MS. Consider taking a closer look, as it could be progression hidden in plain view5,6
IDENTIFYING PROGRESSION IN RELAPSING MS AND
ACTIVE SPMS7
IDENTIFYING PROGRESSION IN RELAPSING MS AND ACTIVE SPMS7
Both terms describe a patient with RMS still showing some level of disease activity, as defined by relapses or inflammatory activity measured in an MRI, while also experiencing signs of disability progression that cannot be directly attributed to relapses.7
SEE HOW MAYZENT CANHELP YOUR PATIENTS
GET PATIENTS STARTED ON MAYZENT®
EDSS, Expanded Disability Status Scale; MOA, mechanism of action; MOD, mechanism of disease; MS, multiple sclerosis; RMS, relapsing MS; SPMS, secondary progressive MS.
References: 1. Mayzent [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2. Kappos L, Bar-Or A, Cree BAC, et al; for the EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. 3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. 4. Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349-1357. 5. MS Signs and Symptoms. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms. Accessed July 29, 2022. 6. Other Conditions to Rule Out. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/Symptoms-Diagnosis/Other-Conditions-to-Rule-Out. Accessed July 29, 2022. 7. Types of MS. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/What-is-MS/Types-of-MS. Accessed July 29, 2022. 8. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. Brain. 1989;112(pt 1):133-146.